Indegene Limited
NSE: INDGN · Healthcare Research, Analytics & Technology · sector
₹601.75NSE close 2026-10-26
Key numbers
Market cap₹14,472 cr
Price₹601.75
52w high / low₹627 / ₹414
P/E36.0xSector median 27.9x
P/B4.6xSector median 3.0x
Book value₹130.5
Dividend yield0.33%Sector median 0.34%
ROE13.9%Sector median 6.1%
ROCE17.4%Sector median 9.8%
OPM16.2%Sector median 8.4%
Debt / equity0.00xSector median 0.01x
EV/EBITDA21.0xSector median 14.8x
Interest cover24.9x
Current ratio2.41x
Sales growth 3y–Sector median +7.2%
Profit growth 3y–Sector median -13.6%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 9 companies in Healthcare Research, Analytics & Technology (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹1,481 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 24.9x in the last 12 months.
- Operating cash flow was below net profit in 0 of the last 3 years.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 20% of net profit in the last 12 months.
- Debtor days went from 91 (FY24) to 102 (FY26).
- Dividend paid in 1 of the last 3 financial years.
- Price ₹601.75 on 2026-10-26: -4.0% from the 52-week high, +45.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹695.90 · low ₹423.50
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 |
| EBITDA | 126 | 132 | 148 | 155 | 141 | 160 | 143 | 174 |
| OPM % | 18.4% | 18.3% | 19.5% | 20.4% | 17.5% | 16.9% | 14.3% | 16.4% |
| Other income | 21 | 38 | 26 | 22 | 20 | 19 | 11 | 29 |
| Net profit | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 |
| EPS (₹) | 3.84 | 4.59 | 4.91 | 4.86 | 4.26 | 4.29 | 3.32 | 4.84 |
| Revenue YoY | +17.1% | +30.8% | +32.8% | +39.7% | ||||
| Profit YoY | +11.3% | -6.2% | -32.2% | -0.2% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|
| Revenue | 2,590 | 2,839 | 3,510 | 3,813 |
| EBITDA | 508 | 534 | 599 | 618 |
| Net profit | 345 | 407 | 401 | 401 |
| EPS (₹) | 15.19 | 17.15 | 16.72 | 16.71 |
| Revenue growth | +9.6% | +23.6% | +30.4% | |
| Profit growth | +18.0% | -1.4% | -7.9% | |
| Dividend / share (₹) | – | – | 2.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | +30.4% |
| Net profit | – | – | -7.9% |
| EPS | – | – | – |
| Share price | – | -5.7% (2y) | +4.7% |
Balance sheet
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Shareholders' equity | 1,429 | 2,616 | 3,139 |
| Borrowings | 403 | 0 | 0 |
| Cash & equivalents | 988 | 1,664 | 1,481 |
| Total assets | 2,546 | 3,326 | 4,620 |
| Fixed assets | 114 | 135 | 194 |
| Capital work in progress | – | 4 | 12 |
| Investments | 0 | 0 | 0 |
| Receivables | 648 | 751 | 982 |
| Inventory | 0 | 0 | 0 |
| Payables | 118 | 93 | 181 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash from operations | 508 | 442 | 651 |
| Cash from investing | -327 | -683 | -512 |
| Cash from financing | -66 | 288 | -83 |
| Capex | 11 | 30 | 44 |
| Free cash flow | 497 | 412 | 606 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| ROE % | 24.1% | 15.5% | 12.8% |
| ROCE % | 27.7% | 21.5% | 17.3% |
| Debtor days | 91 | 97 | 102 |
| Inventory days | 0 | 0 | 0 |
| Payable days | 17 | 12 | 19 |
| Cash conversion cycle (days) | 74 | 85 | 83 |
| Working capital days | 166 | 253 | 159 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| FIIs | 12.40% |
| DIIs | 15.82% |
| of which Mutual funds | 12.25% |
| of which Insurance | 0.12% |
| Public (non-institutions) | 71.77% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public holders above 1% | % |
|---|---|
| Nadathur Fareast PTE Ltd | 21.87% |
| Manish Gupta | 8.91% |
| Rajesh Bhaskaran Nair | 7.14% |
| Sanjay S Parikh | 4.98% |
| Quant Mutual Fund - Qsif Equity Long Short Fund | 4.68% |
| ICICI Prudential Technology Fund | 3.11% |
| Government Pension Fund Global | 2.77% |
| Gaurav Kapoor | 2.60% |
| Vida Trustees Private Limited | 2.32% |
| Anand Kiran | 2.16% |
| Aarabhi Partners Consultants Llp | 2.09% |
| Sundaram Mutual Fund - Sundaram Aggressive Hybrid Fund | 1.94% |
| Chestnut Associates Ptc Limited | 1.43% |
| Sycamore Philanthropy (Ptc) Limited | 1.43% |
| Fidelity Funds - India Focus Fund | 1.34% |
1,32,280 shareholders. Pledged: – of promoter shares.
Peers in Healthcare Research, Analytics & Technology
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SYNGENE | ₹14,527 cr | 65.4x | 3.0x | 4.6% | 7.0% | 19.8% | +5.4% | 0.35% |
| INDGN | ₹14,472 cr | 36.0x | 4.6x | 13.9% | 17.4% | 16.2% | – | 0.33% |
| SUVEN | ₹6,917 cr | – | 11.7x | -100.5% | -59.5% | -4,155.5% | -19.3% | – |
| VIMTALABS | ₹2,185 cr | 27.4x | 4.8x | 19.1% | 23.5% | 34.3% | +8.9% | 0.20% |
| BI | ₹189 cr | 4.3x | 1.0x | 2.3% | 7.0% | 8.4% | +274.4% | – |
| TAKE | ₹154 cr | 12.1x | 5.0x | 49.8% | 20.1% | -2.0% | -34.1% | – |
| NOVELIX | ₹141 cr | 31.7x | 3.0x | 11.3% | 8.8% | 3.1% | +411.3% | – |
| JSTL | ₹102 cr | 28.5x | 1.4x | 6.1% | 9.8% | 20.5% | +19.4% | 0.97% |
| ADESHWAR | ₹23 cr | 18.0x | 0.9x | 5.5% | 10.2% | 4.9% | -12.0% | – |
All 9 companies in Healthcare Research, Analytics & Technology →
Business segments (FY26)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Enterprise Commercial Solutions | ₹2,460 cr | 70.1% | ₹449 cr | 18.3% |
| Enterprise Medical Solutions | ₹930 cr | 26.5% | ₹244 cr | 26.2% |
| Others | ₹120 cr | 3.4% | ₹-33 cr | -27.2% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-31 | Dividend | Dividend - Rs 2.25 Per Share |
| 2025-06-13 | Dividend | Dividend - Rs 2 Per Share |
| 2024-08-29 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Other Professional, Scientific & Technical activities: Other Professional, Scientific & Technical activities
| Sector | Healthcare |
| Industry | Healthcare Research, Analytics & Technology |
| Sub-industry | Healthcare Research, Analytics & Technology |
| Symbol | INDGN |
| BSE code | 544172 |
| ISIN | INE065X01017 |
| Face value | ₹2.0 |
| Incorporated | 1998-10-16 |
| Website | https://www.indegene.com |
| Plants (India / abroad) | 0 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.